Pancreatic exocrine insufficiency is usual in cystic fibrosis' 2 and it is not surprising that low serum concentrations of fat soluble vitamins, particularly A and E, have been observed.3 Low serum vitamin A concentrations may not be the result of malabsorption alone, as increased liver concentrations of vitamin A with low serum concentrations were reported by Underwood and Denning in 1972. 4 Even with oral vitamin supplements, however, serum concentrations in cystic fibrosis patients remain below those of control populations.4s
Chronic hypervitaminosis A may exist for many years among members of the general public without recognition,6 resulting eventually in hepatocellular damage and hepatic fibrosis.7 Pre-existing liver disease may also affect the capacity of the organ to transport the vitamin into the circulation, thus potentiating its hepatotoxicity. As cystic fibrosis is a condition predisposing to liver pathology, it is not certain that supplementation of all patients with vitamin A is advisable. Doses of vitamin A need not be large to cause toxicity, as this has occurred with oral intakes of 20-45 000 IU/day.5 Raised plasma retinyl ester concentrations and biochemical evidence of liver damage have been reported in normal control subjects taking moderate doses only (10 000 IU or less daily) of the vitamin. 9 It has been recommended that cystic fibrosis patients be supplemented with 10-25000 IU/ day,"' but little is known of how well these supplements are absorbed. 2 ). The results of the absorption test are also There was no significant difference in the age presented as the maximum rise in plasma retinyl distribution of the patients and control subjects esters (A RE) and the area under the curve (Table) . Serum C reactive protein concentra-(AUC), the baseline being taken as the fasting tions were normal (<6 mg/l) in six of nine cystic value (Fig 3A and B) . The median values in fibrosis patients and not significantly raised 10-9 mg/l) in the remaining three. results (<20% , Table) . These results, in conjunction with low plasma carotene values obtained in eight of nine patients (Table) , indicate that it is very likely that all patients had significant malabsorption. All patients had a clinical requirement for pancreatic enzyme supplements, although these were not well tolerated (and not taken) by one patient (patient 7).
Discussion
Retinol is absorbed by a carrier mediated passive absorption process under physiological conditions, and by simple passive absorption at pharmacological concentrations." Absorption is dependent on a number of factors, including the presence of pancreatic enzymes and bile salts. Esterification of the newly absorbed retinol by acyl-Co A: retinyl acyl transferase within the enterocyte is reported to be normal in cystic fibrosis. 9 The newly esterified vitamin A is then transported to the liver in association with chylomicron remnants.20
Observations on baseline vitamin A status of cystic fibrosis patients in this study are similar to those reported in other studies.4`Few data are available on vitamin A absorption in cystic fibrosis, but in our study of nine patients, all of whom had pancreatic insufficiency, some absorbed significant quantities of the preformed vitamin while others did not. It seems that in some patients, mechanisms for vitamin A absorption are not compromised. This wide variation in absorption of vitamin A is in keeping with observations reported recently on faecal losses of the vitamin in cystic fibrosis."
Acute toxicity results from the ingestion of large quantities of the vitamin over a short period of time, leading to the appearance of free retinol (that is, not bound to retinol binding protein) in the circulation. Persistent consumption of smaller quantities of vitamin A over a prolonged period may result in chronic hypervitaminosis A, with an increase in circulating vitamin A and in the ratio of ester to alcohol forms.22 The considerably raised fasting plasma retinyl ester concentration of 303 nmol/l seen in patient 9 (who was taking 41000 IU/day) suggests chronic hypervitaminosis A, although the patient was entirely asymptomatic. Traditionally, chronic hypervitaminosis A has been associated with an intake of larger quantities of the vitamin (>100000 IU/day) over a prolonged period.
However, the daily intake required to produce toxicity is very variable, ranging from 5000 IU'2 to 1 400 000 lU,24 and the length of time required is also variable." 6 It has also been suggested that there is an inherited variability of susceptibility to vitamin A toxicity.27
The toxicity of vitamin A may be modulated by a number of factors, being potentiated by alcohol20 and protein-energy malnutrition29; a degree of protection is afforded by tocopherol, taurine, and zinc."' In cystic fibrosis the abnormality of vitamin A metabolism seems to be related to an inability of the liver to mobilise its stores of the vitamin, and perhaps it is not surprising that the patient with raised plasma retinyl esters was asymptomatic and had a normal plasma retinol concentration. This may be analogous to a report of a non-cystic fibrosis patient who had liver damage from massive vitamin A deposition, together with a depressed serum vitamin A concentration. He had consumed up to 25 000 IU/day of the vitamin for seven years and had a degree of protein-energy malnutrition as a result of a poor diet.29
Despite having the highest vitamin A absorption parameters, patient 9 ranked only 4th, 3rd, and 2nd for plasma retinol, carotenes, and serum retinol binding proteins concentrations respectively. Animal studies suggest that over supplementation may also suppress retinol binding proteins synthesis,3' thus further complicating the situation.
Our results suggest that care should be taken with preformed vitamin A supplementation as some cystic fibrosis patients may be at risk of developing hypervitaminosis A if oversupplemented.
The lower plasma carotene concentrations seen in the cystic fibrosis patients suggest that preformed vitamin A supplementation is necessary, as these patients may not be able to meet their daily requirements for this vitamin from dietary carotene alone.
The susceptibility of the liver to injury by increased stores of vitamin A in cystic fibrosis patients, expecially those with liver dysfunction, is not known. It seems prudent therefore to assess in some way the extent of a patient's vitamin A stores, but unfortunately no simple non-invasive technique is available yet. Periodic estimation of fasting plasma retinyl esters seems to be the only option available at present; however, the plasma retinyl ester concentration may be raised only when liver stores of vitamin A are saturated. Further difficulties in interpretation may occur as plasma ester concentrations may be raised as a consequence of liver pathology. 6 We are currently investigating the possible use of other vitamin A metabolites as markers of hepatic vitamin A stores.
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